Panacea Biotec Ltd posts ₹11.91 crore Q2 FY27 net profit

Panacea Biotec Ltd posted consolidated net profit of ₹11.91 crore in Q2 FY27, reversing a ₹14.01 crore loss a year earlier, as revenue from operations rose 34.4% year on year to ₹189.67 crore. The September-quarter result marks a return to profitability, although revenue declined 5.0% from the preceding quarter.

How did Panacea Biotec perform in Q2 FY27?

Panacea Biotec reported consolidated total income of ₹196.27 crore for the quarter ended September 30, 2026, up 33.0% from ₹147.53 crore in Q2 FY26. Revenue from operations increased to ₹189.67 crore from ₹141.13 crore a year earlier. The company filed its unaudited quarterly and half-year results with the exchanges after its board meeting on November 14, 2026.

The company recorded profit before tax of ₹16.99 crore, compared with a pre-tax loss of ₹19.17 crore in the year-earlier period. Consolidated net profit was ₹11.91 crore, against a net loss of ₹14.01 crore in Q2 FY26. Basic earnings per share stood at ₹1.90, compared with negative ₹2.27 a year earlier.

What changed from the previous quarter and last year?

Panacea Biotec's revenue was lower sequentially, falling 5.0% from ₹199.57 crore in Q1 FY27. Total income declined 3.7% quarter on quarter. However, expenses decreased 10.3% to ₹182.05 crore from ₹202.98 crore, which supported a substantial improvement in profitability.

Net profit increased from ₹2.20 crore in the June 2026 quarter. Profit before tax rose from ₹3.57 crore, while basic EPS increased from ₹0.38 to ₹1.90. The quarter also included exceptional income of ₹2.70 crore. This item formed part of the reported profit before tax and should be considered when comparing the quarter with regular operating performance.

The year-on-year change was more pronounced because the company had reported losses in Q2 FY26. Operating profit was ₹15.50 crore in Q2 FY27, compared with an operating loss of ₹17.79 crore a year earlier. Net profit margin improved to 6.07% from negative 9.50% in Q2 FY26, while the operating margin moved to positive territory.

What did the board and auditors report?

Panacea Biotec's board approved the unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2026. The company had earlier notified BSE and NSE that its board would consider the provisional quarterly results on November 14.

The statutory auditors issued unmodified limited-review reports on the financial results. An unmodified report means the auditors did not modify their conclusion on the reviewed statements. The reports nevertheless included a note on material uncertainty related to going concern for the standalone company because of negative retained earnings.

The filing also stated that the trading window would remain closed until November 16, 2026. The disclosed going-concern note relates to the standalone entity and is an important consideration alongside the consolidated profit reported for the quarter.

Why do the Q2 FY27 results matter for investors?

The Q2 result provides evidence of a marked improvement over the loss-making period a year earlier. Revenue growth of 34.4% and lower sequential expenses helped Panacea Biotec report positive profit before tax and net profit. The company has now reported profits in each of the first two quarters of FY27, with Q2 profit higher than the ₹2.20 crore reported in Q1.

At the same time, the sequential decline in revenue and the presence of exceptional income are relevant to assessing the quality and repeatability of earnings. The standalone going-concern uncertainty also remains a disclosed financial issue. No share-price movement or market reaction was provided in the company material, so the results do not establish a direct impact on the stock.

For the broader healthcare and pharmaceutical business, the figures show that revenue expansion alone was not the only factor in the quarterly turnaround. The reduction in total expenses from Q1 FY27 was significant to the improvement in pre-tax profit. Investors can compare future revenue, expense levels, margins and exceptional items against this quarter's base.

Conclusion

Panacea Biotec's Q2 FY27 consolidated result showed a return to profit, with ₹11.91 crore of net profit against a ₹14.01 crore loss in the previous year's quarter. Revenue rose to ₹189.67 crore and expenses declined from the immediately preceding quarter, resulting in improved margins and earnings per share.

The next key disclosures will be subsequent quarterly financial results and any updates on the standalone entity's negative retained earnings and going-concern uncertainty. Investors will also watch whether revenue growth, expense discipline and profitability continue without reliance on exceptional income.